Affiliations: [a]
Department of Neurology, University Clinic Bonn, Bonn, Germany
| [b]
Department of Internal Medicine I, University Clinic Bonn, Bonn, Germany
| [c]
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Correspondence:
[*]
Address for correspondence: Oliver Kaut, MD, PhD, Department of Neurology, University of Bonn, Venusberg-Campus 1,
53127 Bonn, Germany. Tel.: +49 228 287 14431; E-mail: oliver.kaut@ukbonn.de.
Abstract: BACKGROUND:Gastrointestinal dysfunctions are common in Parkinson’s disease. Their management is still challenging and new treatment options are needed. OBJECTIVE:To test whether transcutaneous vagal nerve stimulation can improve gastrointestinal dysfunction in patients with Parkinson’s disease. METHODS:We performed a randomized double-blind pilot study enrolling patients suffering from Parkinson’s disease with gastroenteric complaints. Patients were randomized to use either a sham-device or to stimulate the vagal nerve with an electric device over the course of four weeks with four stimulations per day. Ten patients (aged 69.6±4.6 years) were randomized for the intervention group, and nine patients (aged 67.2±6.3 years) used a sham-device. Clinical outcome was evaluated using the Gastrointestinal Symptom Rating Scale whereas gastrointestinal motility was measured with the 13C-octanoic acid breath test. RESULTS:In the treatment group, vagal nerve stimulation improved the Gastrointestinal Symptom Rating Scale comparing before and after stimulation (before, 8.7±6.09; after 5.67±3.08; p-value 0.48). This improvement was not observed in the sham group (before, 7.44±4.85; after, 5.67±3.08; p-value 0.16). In the 13C-octanoic acid breath test no significant changes were detectable. CONCLUSIONS:Vagal nerve stimulation is well tolerated with no side effects and may be a promising non-invasive therapy option to improve gastroenteric symptoms in Parkinson’s disease.
